FDA “Not Approvable” Letter Questions Benefit Of Endo’s Frova In Menstrual Migraine
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency indicates potential for vascular events is another reason frovatriptan is "not approvable" for short-term prevention of menstrual migraine.
You may also be interested in...
GSK’s Treximet Could Face Market Headaches
Potential hurdles for Pozen-partnered migraine combo drug include BiDil-like woes and switchover problems.
GSK’s Treximet Could Face Market Headaches
Potential hurdles for Pozen-partnered migraine combo drug include BiDil-like woes and switchover problems.
Endo Withdraws Frova sNDA For Menstrual Migraine Prevention
Action comes days after former Johnson & Johnson exec Holveck takes the helm as president and CEO.